Buscar
Mostrando ítems 1-10 de 19
Artículo
Obesity dependent metabolic signatures associated with nonalcoholic fatty liver disease progression
(2012)
Our understanding of the mechanisms by which nonalcoholic fatty liver disease (NAFLD) progresses from simple steatosis to steatohepatitis (NASH) is still very limited. Despite the growing number of studies linking the ...
Artículo
Disease severity predicts higher healthcare costs among hospitalized nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH) patients in Spain
(Lippincott, Williams & Wilkins, 2020)
The rising prevalence of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) presents many public health challenges, including a substantial impact on healthcare resource utilization and costs. ...
Artículo
Impact of a Loss-of-Function Variant in HSD17B13 on Hepatic Decompensation and Mortality in Cirrhotic Patients
(MDPI AG, 2022)
Abstract: A common splice variant in HSD17B13 (rs72613567:TA) was recently found to be associated with a reduced risk of developing chronic liver disease in NAFLD patients and a reduced risk of progression to advanced ...
Artículo
Stratification of patients in NASH clinical trials: a pitfall for trial success
(Elsevier, 2020)
Identifying the most effective therapeutic intervention in patients with NAFLD is challenging. Precise stratification in clinical trials is key to ensuring the inclusion of patients who will benefit (and not those who will ...
Artículo
The European NAFLD Registry: A real-world longitudinal cohort study of nonalcoholic fatty liver disease
(Elsevier, 2020)
Non-Alcoholic Fatty Liver Disease (NAFLD), a progressive liver disease that is closely associated with obesity, type 2 diabetes, hypertension and dyslipidaemia, represents an increasing global public health challenge. There ...
Artículo
Metabolic subtypes of patients with NAFLD exhibit distinctive cardiovascular risk profiles
(Willey, 2022)
Background and Aims We previously identified subsets of patients with NAFLD with different metabolic phenotypes. Here we align metabolomic signatures with cardiovascular disease (CVD) and genetic risk factors. Approach ...
Artículo
Management of NAFLD patients with advanced fibrosis
(Wiley-Blackwell, 2021-06-21)
The prevalence of non alcoholic fatty liver disease (NAFLD) has increased to 25% in the general population and could double by 2030. Liver fibrosis is the main indicator of morbidity and mortality and recent estimations ...
Artículo
Detailed stratified GWAS analysis for severe COVID-19 in four European populations
(OXFORD UNIV PRESS, 2022)
Metabolic associated fatty liver disease (MAFLD) is the most prevalent form of liver disease worldwide, accounting for a high liver-related mortality and morbidity with extensive multi organ involvement. This entity has ...
Artículo
The altered serum lipidome and its diagnostic potential for Non-Alcoholic Fatty Liver (NAFL)-associated hepatocellular carcinoma
(Elsevier, 2021-12)
Background Non-alcoholic fatty liver disease (NAFLD) is affecting more people globally. Indeed, NAFLD is a spectrum of metabolic dysfunctions that can progress to hepatocellular carcinoma (NAFLD-HCC). This development can ...
Artículo
Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases
(Frontiers Media, 2021-11-24)
Metabolic associated fatty liver disease (MAFLD) is the most prevalent form of liver disease worldwide, accounting for a high liver-related mortality and morbidity with extensive multi-organ involvement. This entity has ...